H. Taskaynatan, “Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study ”, annalsmedres, vol. 27, no. 1, pp. 0029–0033, May 2021.